Gyros' nanoliter-scale immunoassay platform proves commercial success for US-based CRO
Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, today announced that MPI Research (www.mpiresearch.com) has become the first contract research organization (CRO) in North America to secure a second Gyrolab™ xP workstation, a nanoliter-scale immunoassay platform.
Data from immunoassays underpin many critical decisions within complex workflows for the development of biopharmaceuticals. The automated, precise, nanoliter-scale immunoassay platform from Gyros enables project-specific biomarker, pharmacokinetic (PK), immunogenicity assays and impurity tests to be developed quickly, and to easily transfer the running of established assays. Since installing its first Gyrolab xP workstation in April 2011, MPI Research has developed more than 25 novel assays using the platform. The ability to work with nanoliter volumes maximises the number of assays that can be performed on samples that are often scarce.
Roger Hayes, PhD, Vice President and General Manager of Laboratory Sciences at MPI Research, commented: “Part of our mission is to exceed expectations, which means investing in innovative technology that can make a real difference to the way we work. We have seen great success both scientifically and commercially with the Gyrolab workstation, and look forward to building on this with additional platforms.”
Erik Walldén, CEO, Gyros, added: “We are very pleased that MPI Research has seen success with the Gyrolab platform. With the growing trend for outsourcing to CRO’s, we are also seeing these companies increasing their capacity for our technology.”